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Summary
Constitutional mutations of the WT1 gene, encoding a
zinc-finger transcription factor involved in renal and go-
nadal development, are found in most patients with
Denys-Drash syndrome (DDS), or diffuse mesangial scle-
rosis (DMS) associated with pseudohermaphroditism
and/or Wilms tumor (WT). Most mutations in DDS
patients lie in exon 8 or exon 9, encoding zinc finger 2
or zinc finger 3, respectively, with a hot spot (R394W)
in exon 9. We analyzed a series of 24 patients, 10 with
isolated DMS (IDMS), 10 with DDS, and 4 with uro-
genital abnormalities and/or WT. We report WT1 het-
erozygous mutations in 16 patients, 4 of whom pre-
sented with IDMS. One male and two female IDMS
patients with WT1 mutations underwent normal pu-
berty. Twomutations associated with IDMS are different
from those described in DDS patients. No WT1 muta-
tions were detected in the six other IDMS patients, sug-
gesting genetic heterogeneity of this disease.We analyzed
genotype/phenotype correlations, on the basis of the
constitution of a WT1 mutation database of 84 germ-
line mutations, to compare the distribution and type of
mutations, according to the different symptoms. This
demonstrated (1) the association between mutations in
exons 8 and 9 and DMS; (2) among patients with DMS,
a higher frequency of exon 8 mutations among 46,XY
patients with female phenotype than among 46,XY pa-
tients with sexual ambiguity or male phenotype; and (3)
statistically significant evidence that mutations in exons
8 and 9 preferentially affect amino acids with different
functions.
Received December 9, 1997; accepted for publication January 30,
1998; electronically published March 20, 1998.
Address for correspondence and reprints: Dr. C. Jeanpierre,
INSERM U383, Clinique Maurice Lamy, Hoˆpital Necker-Enfants Ma-
lades, 149 rue de Se`vres, 75743 Paris Cedex 15, France. E-mail:
jeanpierre@necker.fr
 1998 by The American Society of Human Genetics. All rights reserved.
0002-9297/98/6204-0014$02.00
Introduction
The WT1 gene encodes a zinc-finger transcription factor
involved in kidney and gonadal development (Pritchard-
Jones et al. 1990). In fetal kidney, it is expressed in the
condensing mesenchyme, the renal vesicle, and devel-
oping podocytes. The other main sites are the genital
ridge, fetal gonads, and the mesothelium. Knockout of
this gene in mouse resulted in the absence of renal and
gonadal development (Kreidberg et al. 1993). The gene
has 10 exons, of which exons 1–6 encode a proline/
glutamine-rich transcriptional-regulation region and ex-
ons 7–10 encode the four zinc fingers of the DNA-bind-
ing domain. Different functional domains involved
either in repression or in activation of transcription
(Wang et al. 1993, 1995) and a region involved in homo-
dimerization of the protein (Moffett et al. 1995) have
been characterized. Two alternative splicing regions, one
corresponding to the 17 amino acids encoded by exon
5 and the other corresponding to amino acids KTS en-
coded by the 3′ end of exon 9, allow synthesis of four
isoforms with conserved relative amounts (Haber et al.
1991), different binding specificities (Bickmore et al.
1992; Drummond et al. 1994), and different subnuclear
localizations (Englert et al. 1995; Larsson et al. 1995).
The exon 5–containing isoforms contain an additional
dominant repressor domain (Wang et al. 1995), and their
relative proportions may vary during renal development
(Renshaw et al. 1997). The KTS isoforms bind to a
consensus sequence identical to that for EGR1 and pres-
ent in numerous genes, including IGF2 (Drummond et
al. 1992), PDGFA (Wang et al. 1992), and WT1 (Rup-
precht et al. 1994), in agreement with a role in the reg-
ulation of transcription. Transient transfection assays
have confirmed that WT1 may activate or suppress these
genes, but the physiological and functional significance
of these effects is still not known. The KTS proteins
associate with splicing factors and may have a role in
RNA splicing (Larsson et al. 1995).
Constitutional heterozygous intragenic mutations of
Jeanpierre et al.: WT1 Mutations and IDMS 825
WT1 have been described in most patients with Denys-
Drash syndrome (DDS) (MIM 194070 and 194080) (for
a review, see Little and Wells 1997). This syndrome in-
cludes a specific nephropathy characterized by diffuse
mesangial sclerosis (DMS), male pseudohermaphrodi-
tism, and/or Wilms tumor (WT) (Denys et al. 1967;
Drash et al. 1970). DDS patients with a 46,XY karyo-
type present with ambiguous or female external genitalia
and dysgenic gonads. In contrast, 46,XX children have
a normal female phenotype. Among the five 46,XX pa-
tients whose gonads were tested, four had apparently
normal ovaries, and only one had dysgenic gonads (Jean-
pierre et al. 1998). No data concerning puberty in the
46,XX DDS patients are available. Most of the muta-
tions in the DDS patients are missense changes in either
exon 8, coding for zinc finger 2, or exon 9, coding for
zinc finger 3, with a hot spot at position 1180 in the
codon for arginine 394, which is predicted to be involved
in the interaction with the consensus DNA sequence.
The reasons for heterogeneity of the clinical features
of patients with WT1 mutations are still poorly under-
stood. One way to elucidate the role of constitutional
mutations, in the expression of the different clinical fea-
tures, is to analyze WT1 in patients presenting with dif-
ferent combinations of these symptoms. Mutations have
been described (1) in male patients with cryptorchidism
and/or hypospadias and WT (Pelletier at al. 1991; Huff
et al. 1995; Nordensko¨ld et al. 1995b) and (2) in patients
presenting with WT only, either unilaterally or bilater-
ally, including one familial case (Little et al. 1992; Aka-
saka et al. 1993; Coppes et al. 1993; Kaplinsky et al.
1996; Schumacher et al. 1997). However, no mutations
have been identified in patients with isolated XY gonadal
dysgenesis (Nordenskjo¨ld et al. 1995a). No data con-
cerning patients presenting with isolated DMS (IDMS)
are available. This early-onset nephropathy, which most
often progresses to end-stage renal failure (ESRF) at ∼3
years of age, can occur in the absence of other abnor-
malities, and there is no histological difference between
this form and that in DDS patients (Habib et al. 1993).
Analysis of WT1 in patients with IDMS would be
helpful not only in deciphering the role of WT1 in renal
and genital development but also in providing a molec-
ular definition of IDMS related to DDS. We therefore
sequenced the WT1 gene from each of 10 patients with
IDMS. We identified mutations in four cases, suggesting
that IDMS could be a clinical form of DDS. However,
no mutation was detected in the six other patients, sug-
gesting genetic heterogeneity of IDMS. We also char-
acterized WT1 mutations in 10 new patients with DDS
and in 4 patients with urogenital abnormalities and/or
WT and no nephropathy.
We recently developed software and a database for
the analysis of WT1 mutations (Jeanpierre et al. 1998).
The mutations we describe in this article were added to
this database. Using this tool, we performed comput-
erized analyses of the distribution and type of mutations
in the gene, according to clinical features. These analyses
suggest that exon 8 and exon 9 mutations may not be
equivalent for genital development impairment associ-
ated with DMS, in DDS patients. With the accumulation
of data, genotype/phenotype-correlation analyses based
on utilization of this database and the associated soft-
ware will help in the understanding of the roles of dif-
ferent isoforms and regions of the WT1 protein, in de-
velopment and cancer.
Patients and Methods
Patients
Ten patients with IDMS were selected on the basis of
the presence of DMS in the absence of urogenital ab-
normality and WT (table 1). Patients P2, P8, and P10
were male children; patients P1, P3–P7, and P9 were
46,XX female children. One male and three female pa-
tients underwent normal pubertal development, whereas
the other patients are still too young. WT was not found
during follow-up exams performed within 2 mo–12.5
years. There were no other congenital abnormalities and
no family history of developmental abnormalities or re-
nal problems, for any of these patients. The parents of
patient P6 were consanguineous.
Ten patients presenting with DMS in a context of DDS
also were studied (table 1). Patients P11–P13 and
P15–P20 had the 46,XY karyotype and genital abnor-
malities ranging from testicular ectopia to female phe-
notype. Patient P14 had the 46,XX karyotype and streak
ovaries. Unilateral WT was diagnosed in two patients,
and gonadoblastoma was diagnosed in two other
patients.
For these 20 patients with DMS, the age at which the
first symptoms of nephrotic syndrome were observed
varied, from birth to 4.3 years. Age at ESRF was 18
d–4.5 years, except for patient P19, who developed
ESRF at age 11 years 6 mo. Patients P11 and P13 died
of ESRF during the 1st mo of life. Patients P17 and P18,
who were 6 years old and 2.9 years old, respectively,
had not yet developed ESRF. DMS was ascertained his-
tologically in all these patients.
Two 46,XY patients (P22 and P23) with urogenital
abnormalities and WT but no DMS, a 46,XY patient
(P24) with ambiguous genitalia, WT, and mild protein-
uria, and a 46,XX patient (P21) with WT only also were
studied (table 1). The parents of patients P1–P4, P13,
P14, P17, and P21 were available for study. The appro-
priate informed consents were obtained.
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DNA Sequencing
For exon 1, we amplified a 277-bp fragment, using
primers WT256 (5′-AGC CAG AGC AGC AGG GAG
TC-3′) and WT532R (5′-AAC GAC CCG TAA GCC
GAA GC-3′), which correspond to positions 125 bp
and 152 bp, respectively, from the site of translation
initiation (Huff et al. 1995). Exons 2–10 were amplified
by use of primers corresponding to the preceding and
following intronic sequences. The primers and product
lengths were as follows: for exon 2, C147 (5′-AAG CTT
GCG AGA GCA CCG CTG-3′) and C148 (5′-TAA TTT
GCT GTG GGT TAG GAA TTC-3′), 259 bp; for exon
3, C149 (5′-GGC TCA GGA TCT CGT GTC TC-3′)
and C150 (5′-CCA AGT CCG CCG GCT CAT G-3′),
271 bp; for exon 4, C486 (5′-AAA CAG TTG TGT ATT
ATT TTG TGG-3′) and C152 (5′-ACT TTC TTC ATA
AGT TCT AAG CAC-3′), 224 bp; for exon 5, C153 (5′-
CAG ATC CAT GCA TGC TCC ATT C-3′) and C154
(5′-CTC TTG CAT TGC CCC AGG TG-3′), 176 bp; for
exon 6, C178 (5′-AAG CTT CAC TGA CCC TTT TTC
CCT TC-3′) and C177 (5′-GAA TTC CAA AGA GTC
CAT CAG TAA GG-3′), 221 bp; for exon 7, WT1-7S
(5′-AAG ACC TAC GTG AAT GTT CAC A-3′) and
WT1-7AS (5′-TAC AAC ACC TGG ATC AAG ACC T-
3′), 351 bp; for exon 8, C323 (5′-CCT TTA ATG AGA
TCC CCT TTT CC-3′) and 796 (5′-GGG GAA ATG
TGG GGT GTT TCC-3′), 391 bp, or WT89S (5′-TCC
AGC GAA GTG CCT TAG GC-3′) and WT11 (5′-CCT
AGC CCA AGG GAA CAC AG-3′), 257 bp; for exon
9, 798 (5′-TGC AGA CAT TGC AGG CAT GGC AGG-
3′) and 801 (5′-GCA CTA TTC CTT CTC TCA ACT
GAG-3′), 349 bp, or WT12 (5′-CCT CAC TGT GCC
CAC ATT GT-3′) and WT89R (5′-TCC CTC TCA TCA
CAA TTT CAT TC-3′), 221 bp; and, for exon 10, C911
(5′-ACT TCA CTC GGG CCT TGA TAG-3′) and C912
(5′-GTG GAG AGT CAG ACT TGA AAG-3′), 234 bp.
PCR fragments were purified on microspin S400 col-
umns (Pharmacia) or on Wizard columns (Promega Bio-
tec). Sequence reactions were performed by use of either
the same, but fluorescently labeled, primers and the
Thermo-Sequenase fluorescent labeled–primer cycle se-
quencing kit (Amersham) for resolution on an ALF se-
quencer (Pharmacia) or the ABI Prism Dye terminator
sequencing kit for resolution on an ABI sequencer (Per-
kin Elmer).
Restriction Analysis
For analysis of the exon 1 polymorphism, 5 ml of the
PCR products (primers WT256 and WT532R) were di-
gested with 2 U of BbvI (Biolabs). The fragments were
resolved on 10% acrylamide gels, transferred onto a
Biodyne membrane (Pall), and probed, for hybridization,
with one of the radiolabeled primers.
Database
To investigate genotype/phenotype correlations, we
recently developed software and a computerized WT1
mutation database containing 70 germ-line mutations
from the literature (Universal Mutation Database [http:
//www.umd.necker.fr]; Jeanpierre et al. 1998). In brief,
for each mutation, information was provided at the gene
level (exon and codon number, wild-type codon, and
mutant codon), at the protein level (wild-type and mu-
tant amino acid), and at the clinical level, for the clinical
features that developed in patients (nephropathy, kary-
otype/external genitalia/internal reproductive organs,
and presence of unilateral or bilateral WT). Routines
have been developed that allow analysis of the type and
distribution of mutations, according to the clinical
features.
Among the 70 registered mutations, 50 were described
in patients with nephropathy, and 17 were described in
patients without nephropathy (4 patients with genital
abnormalities and WT and 13 patients with WT only,
1 of whom is a familial case). Three patients—two with
WT and nephrotic syndromes not associated with DMS
(Bardeesy et al. 1994; Schmitt et al. 1995) and one with
WT, maldescended testis, and proteinuria (Schumacher
et al. 1997)—were difficult to classify. These patients
were not included in the genotype/phenotype-correlation
analyses. Major rearrangements and mutations in in-
trons were omitted, since they cannot be accommodated
in the present version of the software.
Results
Characterization of WT1 Mutations
Patients with IDMS.—Of the 10 patients with IDMS,
4 were shown to carry a mutation in one WT1 allele.
These mutations involved exon 8 (patient P1), exon 9
(patients P2 and P3), or intron 9 (patient P4) (table 1).
The missense mutation F383L in exon 9 (patient P2) has
not been described previously. The H377Y (patient P1)
and the D396N (patient P3) changes have been described
in several DDS patients. The CrT transition at position
4 of the splice-donor site within intron 9 (patient P4)
has been reported in two patients with Frasier syndrome
(focal and segmental glomerulosclerosis, pseudoherma-
phroditism, and gonadoblastoma) (Barbaux et al. 1997).
None of these mutations were identified in DNA from
the parents. In patients P5–P7, sequencing of the 5′ part
of exon 1 and of the entirety of exons 2–10 did not
identify any mutation. We ascertained the presence of
two copies of the WT1 gene in patient P5, who was
heterozygous for a TrC polymorphism in intron 9, at
position 156 of sequence M80232 (Tadokoro et al.
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Figure 1 Analysis of distribution of WT1 mutations, according
to the presence or absence of nephropathy, by use of the WT1 mutation
database and associated software. Records were selected by use of the
following categories: (1) DMS or nephropathy (60 cases) or (2) no
nephropathy (20 cases). The data provided by the routine “binary
comparison” were exported to the program Excel, to construct the
diagrams. The amino acids and exons affected by the mutations are
indicated below each diagram.
1993). In patients P8–P10, only exons 8 and 9 were
investigated, and no mutation was identified.
Patients with DDS.—Of the 10 patients with DDS, 8
carried WT1 mutations (table 1). The mutations in-
volved exon 8 (patient P11), exon 9 (patients P12–P17),
or intron 9 (patient P18). Two of these muta-
tions—namely, mutations R394Q (patient P15) and
1192delC (patient P16) in exon 9—have not been de-
scribed previously. The absence of the mutation in both
parents was ascertained for three patients (table 1). Se-
quencing of exons 8 and 9 did not reveal any mutation
in patients P19 and P20.
Patients without DMS.—Four patients with urogenital
abnormalities and/or WT also were analyzed for the
presence of constitutional WT1 mutations. Mutations in
exon 3 (patient P21), exon 4 (patient P22), and exon 7
(patients P23 and P24) were identified. Mutations de-
tected in patients P21, P22, and P24 have not been re-
ported previously. The mutations carried by patients P21
and P22 were heterozygous in blood and normal kidney
samples but were homozygous in tumor tissue. This was
in agreement with the previously detected loss of 11p
alleles in the tumor from patient P22 (I. Henry, unpub-
lished data). We also showed that the mutation carried
by patient P21 was inherited from her unaffected father
(table 1).
Characterization of a New Polymorphism in Exon 1
Sequencing of part of exon 1 allowed the identification
of a new polymorphism, with a PIC value of .34. This
TrG variation of the sequence, at position 7 with re-
spect to the ATG initiation codon, created a BbvI site,
which was used to estimate the frequency of the two
alleles, by analysis of the genotypes of 32 unrelated in-
dividuals (data not shown). The frequencies were 32%
(T) and 68% (G).
Genotype/Phenotype Correlations Using the WT1
Mutation Database
Of the 16 mutations we describe in this paper, 14 were
added to the database. The 2 mutations that lie in intron
9 could not be accommodated in the present version of
the software. The number of registered germ-line WT1
mutations increased to 60 for patients with nephropathy
and to 20 for patients without nephropathy. Because of
uncertainty about the clinical diagnosis of patient P24,
his mutation was not included in the correlation
analyses.
The selection of records corresponding to particular
criteria and the computerized analysis of the distribution
of mutations are possible by use of the software package
associated with this database. The routine “binary com-
parison” supplies graphical displays, which allowed us
to compare the distribution of mutations among the dif-
ferent categories of patients, according to the different
clinical features of the DDS triad: nephropathy, genital
abnormalities, and WT.
Distribution of mutations, according to the presence
or absence of nephropathy.—We compared the distri-
bution of mutations in patients selected according to the
criterion “DMS or nephropathy” and patients selected
according to the criterion “no nephropathy” (60 patients
and 20 patients, respectively), independent of the other
symptoms. Note that the description of nephropathy is
not always clearly documented in the published papers.
Thus, in the first category of patients, we included those
with ascertained DMS and those reported as having a
nephropathy. Figure 1 clearly emphasizes (1) that the
mutations involved almost exclusively exons 8 and 9 in
patients with nephropathy (58 of 60 mutations), with a
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Figure 2 Analysis of the distribution of WT1 mutations among patients with nephropathy, according to external genitalia, by use of the
WT1 mutation database and associated software. Records were selected by use of the following categories: (1) DMS or nephropathy and male
genitalia (2 cases); (2) DMS or nephropathy and hypospadias/cryptorchidism (4 cases); (3) DMS or nephropathy and ambiguous genitalia (21
cases); and (4) DMS or nephropathy, 46,XY karyotype, and female external genitalia (13 cases). The key for missense, deletion, insertion, and
stop mutations is as shown in figure 1.
high percentage of missense mutations (55 of 58 mu-
tations, of which 30 involved codon 394) (the mutations
in intron 9 were not taken into account in this analysis,
as explained in Patients and Methods), and (2) that a
large majority of mutations (16 of 20) involved exons
1–7 in the patients without nephropathy, with a large
majority of these mutations (16 of 20) leading to trun-
cated proteins. Among the four missense mutations de-
scribed in patients without nephropathy, one lies in exon
2, which encodes the dimerization domain, one lies in
exon 3, one lies in the alternatively spliced exon 5, and
one is a R394W mutation in exon 9.
Distribution of mutations, according to karyotype/ex-
ternal genitalia associations.—The observation of WT1
mutations in patients with IDMS and, thus, without uro-
genital abnormalities prompted us to analyze the dis-
tribution of mutations in patients with nephropathy/
DMS, according to karyotype/external genitalia associ-
ations. Because of the absence of external genitalia ab-
normalities in 46,XX DDS patients, we assumed that
WT1 mutations do not interfere with normal female
external genitalia development. Thus, the role of WT1
mutations in genitalia abnormalities was investigated
among 46,XY patients. Interestingly, the relative prev-
alence of exon 8 versus exon 9 missense mutations ap-
peared to be higher in 46,XY patients with no male
differentiation of external genitalia (female phenotype;
6 exon 8 mutations vs. 7 exon 9 mutations) than in all
the other categories of patients (ambiguous, hypospa-
dias/cryptorchidism, and male), when the latter were
considered as a single group (4 exon 8 mutations vs. 19
exon 9 mutations), although this did not reach statistical
significance ( ) (fig. 2). Accordingly, the two mu-P  .1
tations described in patients with nephropathy and male
phenotype—namely, patient P2 (this study) and a pre-
viously reported patient (SS/12) with DMS and WT (Jad-
resic et al. 1990; Baird et al. 1992)—lie in exon 9. Note
that neither of these two mutations involves the arginine
codon at position 394. These data suggested that, for
male development, exon 8 mutations could be more del-
eterious than exon 9 mutations. We thus hypothesized
that mutations in exons 8 and 9 could differently disrupt
the normal function of the protein, and we compared
the roles of the amino acids affected by these mutations.
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Figure 3 Diagrammatic representation of exon 8 and exon 9
missense mutations, among the 55 patients with nephropathy, included
in the database. Amino acids either involved in DNA binding (arginine
366, in exon 8; arginine 394 and aspartic acid 396, in exon 9) or
critical for zinc-finger structure (cysteines 355 and 360 and histidines
373 and 377, in exon 8; cysteines 385 and 388 and histidines 401 and
405, in exon 9) are boxed. Amino acids resulting from mutations are
outlined by triangles. Mutations at other positions are indicated in
italics.
We considered amino acids either involved in DNA bind-
ing (arginine 366 in exon 8; arginine 394 and aspartic
acid 396 in exon 9) or critical for zinc-finger structure
(cysteines 355 and 360 and histidines 373 and 377, in
exon 8; cysteines 385 and 388 and histidines 401 and
405, in exon 9) (fig. 3). Among the 55 missense muta-
tions in exons 8 and 9 in patients with nephropathy, a
highly significant ( ) difference appeared, withP ! .001
38 mutations affecting arginine 394/aspartic acid 396
versus a single mutation affecting histidine 401, in exon
9, and with 5 mutations affecting arginine 366 versus 8
mutations affecting cysteine or histidine residues, in exon
8 (fig. 3). However, the distribution of exon 8 mutations
appeared to be different among the 46,XY female pa-
tients, with four mutations affecting arginine 366 versus
two mutations affecting histidine residues (373 and 377)
(fig. 2). Owing to the small number of mutations, the
significance of this observation has to be evaluated.
Discussion
To elucidate the role of constitutional WT1 mutations
in the different clinical components of DDS, we analyzed
a series of 24 patients, 10 of whom presented with IDMS
only. We report the identification of 16 mutations, 6 of
which have not been reported previously. Four muta-
tions were detected in patients with IDMS and involved
exon 8 or exon 9. By computerized analysis of genotype/
phenotype correlations, we demonstrated (1) the asso-
ciation between exon 8 and exon 9 mutations and DMS,
either in its isolated form (IDMS) or within a context
of DDS; (2) a higher frequency of exon 8 mutations
among 46,XY patients with no male external genitalia
development than among patients with sexual ambiguity
or normal male phenotype; and (3) that mutations in
exons 8 and 9, encoding zinc fingers 2 and 3, respec-
tively, clearly affect amino acids with different functions.
We describe the first WT1 mutation, in a male child
(patient P2) with IDMS, as the only abnormality. This
patient had no sexual ambiguity, underwent normal pu-
berty, and had not developed WT by the time of ne-
phrectomy at ages 5 years (left kidney) and 6 years (right
kidney). Thus, his clinical features clearly do not cor-
respond to the definition of DDS. The exon 9 mutation
F383L, detected in this patient, is a newly described
mutation. Since it appeared de novo, it is highly likely
to be responsible for the disease. An exon 9 mutation
was reported previously in another male patient with
DMS, who also developed WT (patient SS in the study
by Baird et al. [1992], or patient 12 in the study by
Jadresic et al. [1990]). The R396D mutation detected in
patient SS/12, which also is a de novo mutation, was
different from the mutation we describe here and also
was reported in three DDS patients presenting with DMS
and ambiguous genitalia, with or without WT. Because
WT is not a constant criterion for DDS, our patient P2
and patient SS/12, both with DMS and male phenotype,
could belong to the same, as-yet-unrecognized category
of DMS patients with WT1 mutations. Thus, mutations
in exon 9 may be compatible with normal male external
genitalia development.
The other three patients with IDMS and WT1 mu-
tations (P1, P3, and P4) were normal 46,XX females,
and two of them had already undergone puberty. Pa-
tients P1 and P3 carry mutations that have been de-
scribed in several DDS patients. The absence of external
genitalia abnormalities in 46,XX DDS patients and the
lack of information concerning the occurrence of pu-
berty in cases reported in the literature raise the question
of the true difference between 46,XX DDS patients and
46,XX IDMS patients. Patient P4 carries a mutation at
position 4 of intron 9. Although we did not demon-
strate that this mutation precludes alternative splicing,
the absence of the mutation in both parents supports its
role in nephropathy. Interestingly, identical mutations at
position 4 of intron 9 were reported recently in two
patients with Frasier syndrome (Barbaux et al. 1997).
Frasier syndrome associates nephropathy and pseudo-
hermaphroditism but differs from DDS by a later age at
onset of nephropathy, the presence of focal and seg-
mental glomerulosclerosis, the absence of WT, and an
increased likelihood of gonadoblastoma. Although the
histological and clinical features of the patients described
in the study by Barbaux et al. (1997) were clearly those
of Frasier syndrome, the renal lesions in our patient P4,
examined by the same physician and the same pathol-
ogist (P.N. and M.-C.G., respectively) as the patients in
the study by Barbaux et al. (1997), are unambiguously
those of DMS. Moreover, the early age at onset of ne-
phropathy, at 4 mo, with ESRF at 14 mo, and the normal
pubertal development and menstruations, at age 11
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years, in this 46,XX girl confirm the diagnosis of IDMS.
This demonstrates heterogeneity of the clinical features
associated with this intron 9 mutation at position 4.
No mutation was identified in the six other patients
with IDMS, either by analysis of exons 8 and 9, in pa-
tients P8–P10, or by analysis of the 5′ part of exon 1
and the entirety of exons 2–10, in patients P5–P7. Thus,
our data suggest the existence of at least two genetic
forms of IDMS: (1) one form could be considered a
variant of DDS, involving a mutation in either exon 8
or exon 9, and (2) the other form could be due to either
another mechanism of inactivation of WT1, which is
different from a mutation in the coding sequence, such
as methylation of the CpG-rich promotor region (Baylin
1997), or maybe to the involvement of another gene,
which is not involved in genital development.
Most of the mutations we detected in DDS patients
were missense changes affecting zinc fingers 2 or 3, and
we demonstrated de novo occurrence for three of them.
Several mutations have already been reported in other
patients. We report the second case (patient P16) of a
frameshift mutation in exon 9, leading to a truncated
protein in zinc finger 3 (Ogawa et al. 1993). We also
identified a new variant mutation at position 394, which
converts an arginine to a glutamine (patient P15). We
describe a mutation at position5 of intron 9 in patient
P18, whose nephropathy was clearly identified as DMS.
Therefore, this mutation is not strictly Frasier syndrome
specific, as was proposed by Barbaux et al. (1997). All
these mutations involving exon 8 or exon 9 presumably
affect the function of regulation of transcription or the
ability to interact with splicing factors, by loss of KTS
and zinc finger 4 (nonsense mutation in patient P16), by
loss of the KTS isoform (intron 9 mutation at position
5 in patient P18), or by alteration of DNA recognition
(missense mutations) (Little et al. 1995). Sequencing of
exons 8 and 9 did not enable us to identify mutations
in patients P19 and P20. For patient P19, the late age
at ESRF (11 years 6 mo) suggests a peculiar form of
DMS. Patient P20 is a male child with cryptorchidism
and DMS, and the clinical diagnosis of DDS versus
IDMS thus may be questionable.
The four mutations we detected in patients without
nephropathy lie outside exons 8 and 9, and three of them
are nonsense mutations producing proteins lacking the
zinc-finger domain. Interestingly, the mutation presented
by patient P21, who had unilateral WT, was inherited
from her asymptomatic father. This is the fourth case of
a transmission of a WT1 mutation, and in all four cases
the mutation was inherited from the father. An exon 6
mutation has been described in a father with WT and
in his son, who has urogenital abnormalities and WT
(Pelletier et al. 1991). However, in all the other cases,
the transmitting father was asymptomatic, and inheri-
tance of an exon 8 or exon 9 mutation has been reported
in children with familial WT or DDS, respectively (Cop-
pes et al. 1992; Kaplinsky et al. 1996). The difference
in or the absence of phenotypic expression of these mu-
tations may be relevant to mosaic, polymorphic, and
tissue-specific imprinting of WT1 (Jinno et al. 1994; Mit-
suya et al. 1997).
Both the heterogeneity of phenotypes associated with
WT1 mutations and the difficulties of manual analysis
of such complex information (Coppes et al. 1993; Huff
1996; Little and Wells 1997) prompted us to develop a
computerized tool (Jeanpierre et al. 1998). This tool al-
lows comparison of the distribution of mutations be-
tween different categories of patients from the database,
sorted according to selected clinical or molecular criteria.
In this article, we report the first analysis of the distri-
bution of WT1 mutations, according to the clinical fea-
tures of the DDS triad. The most striking comparison is
the preponderance of exon 8 and exon 9 missense mu-
tations, in patients with nephropathy, versus mutations
leading to truncated proteins lacking the zinc-finger do-
main, in patients without nephropathy. Mutation
R394W is unambiguously the mutation most frequently
associated with DMS, in DDS patients. However, none
of the 10 IDMS patients whom we studied carry this
mutation. A R394W mutation has been reported in a
female patient presenting with only unilateral WT but
no DMS, at age 7 years (Akasaka et al. 1993). This
patient may be at risk for the development of a late form
of nephropathy. Interestingly, although exon 9 muta-
tions clearly represent a hot spot in patients with ne-
phropathy, our analysis suggests a difference in the roles
of exon 9 and exon 8 mutations, with regard to uro-
genital abnormalities. We found a higher frequency of
exon 8 missense mutations among 46,XY patients with
complete absence of male external genitalia development
(46%) than among patients with normal or disrupted
male genitalia development (17%). Accordingly, the two
patients with normal male development both displayed
exon 9 mutations. Interestingly, although most missense
mutations in the zinc-finger region probably affect DNA
binding, they appear to do so through different mech-
anisms for zinc finger 2 and zinc finger 3. Disruption of
zinc-finger folding by exon 8 mutations at cysteine and
histidine residues (62% of exon 8 mutations) probably
prevents any DNA binding, whereas amino acid changes
at positions critical for DNA-sequence recognition (38%
of exon 8 mutations and 90% of exon 9 mutations)
could create proteins with the potential for binding novel
DNA target sequences. Our analysis of the distribution
of mutations suggests that exon 8 mutations from this
second category could be more deleterious for male dif-
ferentiation. However, analysis of a greater number of
patients is necessary, to reach statistical significance and
to understand how these mutations really affect
development.
832 Am. J. Hum. Genet. 62:824–833, 1998
No correlation could be established between the pres-
ence of any particular mutation and the occurrence of
WT. This is not surprising, because, first, germ-line WT1
mutations confer only a predisposition for development
of this tumor. Other events are required for the tumor
to develop, and we were unable to investigate the prob-
ability of the occurrence of these events. Second, the
status of many patients reported in the literature cannot
be ascertained, because of incomplete data concerning
the occurrence of and age at nephrectomy.
Our study provides new information concerning the
heterogeneity of phenotypes associated with WT1 mu-
tations, by demonstrating that an exon 9 mutation is
compatible with normal male development. Moreover,
computerized analysis of genotype/phenotype correla-
tions suggests that exon 8 and exon 9 mutations carried
by patients with DMS might affect genitalia develop-
ment differently. Analysis of a larger number of patients,
who are characterized clinically with great accuracy, is
necessary to confirm these observations and would con-
tribute to a better understanding of the WT1-gene func-
tion. Moreover, our data suggest the existence of at least
two genetic forms of IDMS: a variant form of DDS due
to an exon 8 or an exon 9 mutation and a form related
to another, as-yet-unidentified mechanism. This implies
that WT1 mutations should be searched for in male and
female patients with IDMS.
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